Exciting results - strengthening the ANP patents on combo therapy with Exon skipping drugs...and the necessary nerdy data to get Sarepta's attention.
Given our PI for the P2B trial is Dr Voit - who is one of the inventors of Micro-dystrophin IP used by Sarepta, maybe the lines of communication are finally open?
No dystrophin, just increase in muscle and reduced inflammation - with a 33% increase in the MyoM1 protein...and modulation of BTLA and FABP4.
Just need the money tox study to drop end of year, and the US door opens a little more.
.
Exciting results - strengthening the ANP patents on combo...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |